Adavosertib Enhances Antitumor Activity of Trastuzumab Deruxtecan in HER2-Expressing Cancers.
DiPeri TP, Evans KW, Raso MG, Zhao M, Rizvi YQ, Zheng X, Wang B, Kirby BP, Kong K, Kahle M, Yap TA, Dumbrava EE, Ajani JA, Fu S, Keyomarsi K, Meric-Bernstam F.
DiPeri TP, et al.
Clin Cancer Res. 2023 Nov 1;29(21):4385-4398. doi: 10.1158/1078-0432.CCR-23-0103.
Clin Cancer Res. 2023.
PMID: 37279095
Free PMC article.